Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412822 | 0.92 | P2RX7 (0.82) | P2RX7ABCB11KMT2ACNR1SPR | |
| SCHEMBL1412806 | 0.92 | P2RX7 (0.82) | P2RX7ABCB11CNR1CNR2SPR | |
| SCHEMBL1412861 | 0.92 | P2RX7 (0.82) | P2RX7ABCB11CNR1CNR2SPR | |
| SCHEMBL1412852 | 0.92 | P2RX7 (1.00) | P2RX7ABCB11SPR | |
| SCHEMBL1412891 | 0.89 | P2RX7 (0.84) | P2RX7ABCB11KMT2AMEN1 | |
| SCHEMBL1412877 | 0.88 | P2RX7 (0.81) | P2RX7ABCB11KMT2ACNR1MEN1 | |
| SCHEMBL1412945 | 0.86 | P2RX7 (0.80) | P2RX7ABCB11 | |
| SCHEMBL1412863 | 0.86 | P2RX7 (0.81) | P2RX7ABCB11SPR | |
| SCHEMBL1412982 | 0.86 | P2RX7 (0.81) | P2RX7ABCB11KMT2ACNR1SPR | |
| SCHEMBL1412815 | 0.85 | P2RX7 (0.87) | P2RX7ABCB11SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448535-B1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2006-03-16 | — | — | US | disclosed |
| CN-1585755-A | Benzamide and heteroarylamide as P2X7 receptor antagonists | PFIZER PROD INC (US) | 2005-02-23 | — | — | CN | disclosed |
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 866/4885KMT2A 3136/4885 |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 443/4885KMT2A 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.